Abingdon-based Verso Biosense, which last year raised £3.9 million in its clinical stage financing round under its previous name of Vivoplex, has signed a product collaboration agreement with Homerton University Hospital in London.
Verso Biosense is an innovator in UK femtech focused on improving women’s health, has signing of a product collaboration agreement with Homerton University Hospital.
Under the agreement, Homerton will use Verso’s uterine monitoring platform and will collaborate with Verso to help refine the technology and biosensing platform to meet the needs of fertility patients. Verso’s platform captures critical in-vivo, biosensing data for optimisation and personalisation of IVF treatment, providing actionable insights for clinicians and patients.
Homerton University Hospital is one of the leading IVF and fertility centres in the UK and is recognised as an innovator in embracing methods and systems that provide better and safer patient care. This includes reviewing and collaborating on novel technologies for the treatment of IVF and fertility.
Charles Dickson, Executive Chairman of Barkby Group, which owns Verso Biosense, said: “I am very excited by this next chapter for Verso Biosense as it partners with some of the UK’s leading IVF and fertility centers to refine its technology and biosensing platform with the aim of optimising fertility treatments for millions of women.
“The opportunity in women’s health is significant and Verso Biosense’s technology has the potential to change diagnostic paradigms across a wide range of further disciplines including endometriosis, fibrosis, menopause and oncology.”